A put ratio spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio. It is generally considered a neutral strategy, although it has the ability to make a profit in up, down and sideways markets. Yes, it can make money no matter which way the market goes, the key is the timing! The strategy involves buying a number of put options and selling more put options further out-of-the-money. The trade is placed when the trader thinks the underlying stock will be stable or slowly move lower and finish around the short put strike at expiry. A fall in implied volatility will benefit the trade and it can also be profitable if the stock moves up early in the trade. The big risk with the trade is a sharp move lower early in the trade. Let’s look at an example using Microsoft (MSFT). Microsoft Ratio Spread Example Buying the April 17 put with a strike price of $390 for around $7.93 and selling 2 of the April 17, 370-strike puts for around $4.00 would create a put ratio spread. As we are selling 2 contracts at $4.00 the trade results in a net credit of $0.07 which is $7 premium. This is the maximum gain above a stock price of $390. Basically, all the puts would expire worthless and the trader keeps the $7 premium. A tent-shaped profit zone exists between $350 and $390 with the maximum gain occurring at $370 and is around $2,000. This is what the trade looks like as of today: You can see the main risk in the trade is a drop in price early on. The blue line is the profit and loss at expiration and the purple line is the T+0 line. T+0 just means “today”. So, we don’t want the stock to get into the profit tent too early. What about in three week’ time? How does the trade look then? Looking a lot better for any price above $365. One advantage of this trade type is it takes advantage of option skew. Notice the contract we are buying has lower volatility (31.44%) than the contract we are selling (34.14%). Buy low, se...

Oracle earnings will show whether its expensive AI bet is starting to pay off CNBC

CHICAGO, March 10, 2026 (GLOBE NEWSWIRE) -- Amplify ETFs , a leading provider of breakthrough ETF solutions, today announced the launch of the Amplify Municipal CEF High Income ETF (YYYM), which is designed to deliver federally tax-advantaged high monthly income through diversified exposure to ~30 U.S. municipal bond closed-end funds (CEFs). YYYM seeks investment results that generally correspond to the price and yield performance of the Nasdaq Municipal Bond CEF High Income™ Index (the “Index”). The Index measures the performance of 30 U.S. municipal bond closed-end funds selected through a rules-based methodology focused on tax-exempt high income. The methodology prioritizes fund yield, discount to net asset value (NAV), and liquidity in its selection process. Municipal bond closed-end funds are commonly utilized in income-focused portfolios for their ability to generate federally tax-exempt income. CEFs can trade at a discount or premium to NAV, offering the potential to enhance yield and capital appreciation when purchased below the underlying net asset value. YYYM packages this exposure into a single ETF, offering diversified exposure across professionally managed municipal CEFs while aiming to reduce single-fund concentration risk and simplify implementation in taxable accounts. “Attractive after-tax income remains a key consideration for many investors,” said Christian Magoon, CEO of Amplify ETFs. “Municipal closed-end funds can play an important role in taxable portfolios, particularly when accessed through a disciplined framework that incorporates income, valuation, and liquidity. YYYM delivers that exposure through a transparent, systematic approach.” YYYM’s launch extends Amplify’s leadership in the discounted closed-end fund ETF space. Amplify also offers the Amplify CEF High Income ETF (YYY), which aims to pay a high level of monthly income by providing exposure to a variety of CEF asset classes while prioritizing yield, discount to NAV, and liquidity. ...

In the seven and a half years since Apple Inc. ’s market capitalization broke through the $1 trillion mark, investors have become accustomed to seeing big tech companies command 13-digit valuations in public markets. There are more on the way. SpaceX , the space exploration company controlled by Tesla Inc. founder and world’s richest man Elon Musk , has signaled it is planning a mega-initial public offering in the coming months. Artificial intelligence rivals OpenAI and Anthropic also might go public this year, and their private valuations already have soared into the hundreds of billions of dollars. The SpaceX IPO is expected to raise as much as $50 billion, which would shatter the previous record set by Saudi Aramco ’s $29.4 billion listing in 2019. SpaceX could seek a valuation of more than $1.75 trillion, Bloomberg has reported, though whether public-market investors will be prepared to buy shares supporting that valuation remains to be seen. SpaceX has morphed from a relative underdog in the space industry to an aerospace behemoth that receives billions of dollars in government contracts and serves as a backbone for the US space program. In addition to its rocket launch business, SpaceX owns a satellite-based internet broadband service, Starlink, that has become the company’s main cash flow generator. Following an all-stock acquisition in February of xAI, SpaceX also owns Grok, a money-burning AI operation whose flagship product is the Grok AI assistant. X, the microblogging site previously known as Twitter, rounds out its portfolio of businesses. A SpaceX IPO would be a huge market spectacle as investors large and small get a chance to buy into Musk’s fast-evolving vision to create a combined space and AI powerhouse. Yet skeptics say investors might worry that Musk will deplete SpaceX, a company that is the clear leader in its industry, to fund xAI, one of many players in a crowded field. Why is SpaceX planning an IPO? Even though SpaceX is believed to have si...

Barclays says the chasm between winning and losing stocks in 2022 when Russia invaded Ukraine was huge. Here are their style picks.

Changing Social Security to a flat benefit for all would put both workers and the poor at risk.

- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases - - FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia - - Funding from prominent healthcare investors expected to extend cash runway into 2028 - RESEARCH TRIANGLE PARK, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced financial results for the year ended December 31, 2025, and provided a corporate update. “We are delivering a steady cadence of data and milestones across our pipeline,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “With positive clinical results from both our BEST1 and LCA5 gene therapy programs, new funding for our MERTK program and an upcoming FDA PDUFA date for Phentolamine Ophthalmic Solution 0.75% in presbyopia, we are advancing therapies with both scientific promise and compelling commercial potential. The reauthorization of the U.S. Rare Pediatric Disease Priority Review Voucher program further strengthens our work, reinforcing long‑term incentives that support sustainable investment in rare gene therapy development. With multiple catalysts ahead and a capital‑efficient operating model, we believe Opus is positioned to create significant long‑term value for shareholders.” Pipeline Updates OPGx-BEST1 – Gene Therapy for BEST1-Related IRD Recruitment is ongoing at multiple U.S. sites with two participants treated to date in the Phase 1/2 trial (BIRD-1) that includes p...

NEWARK, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the fourth quarter and full year ended December 31, 2025 as follows: Fourth Quarter: Sales of $48.5 million compared to $43.9 million for the 2024 fourth quarter Gross profit of $12.1 million, or 24.9% of revenue, compared to $10.6 million, or 24.2% of revenue, for the 2024 fourth quarter Operating (loss) income of ($10.6) million, which includes a ($12.2) million intangible asset impairment charge and ($1.2) million of one-time costs, compared to $1.5 million for the 2024 fourth quarter GAAP EPS of ($0.45), which includes ($0.57) for the intangible asset impairment charge net of the related tax benefits, compared to $0.01 for the 2024 fourth quarter Adjusted EBITDA of $5.7 million compared to $3.9 million for the 2024 fourth quarter Backlog of $110.2 million exiting 2025 compared to $90.3 million exiting the third quarter “During the fourth quarter we took a number of decisive actions to remove structural and manufacturing inefficiencies from our global operations. For example, we commenced the realignment of our four thionyl chloride/oil & gas operations into one business within our Battery & Energy Products segment focused on industrial, specialty and telemetry solutions in order to optimize synergies, deepen customer engagement and expand value propositions. We also designed a master brand strategy uniting all acquired sub-brands under the Ultralife brand and aligning sales of the total Ultralife portfolio, and we completed steps to strengthen the operational leadership at our two largest manufacturing facilities. While we were intensely focused on addressing operational improvements during the quarter, strong order flow increased backlog to $110 million at the end of 2025, representing a 22% increase over the third quarter,” said Mike Manna, President and Chief Executive Officer. “As a result, we have entered 2026 from a position of strength, bett...

Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug CHAPEL HILL, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the year ended December 31, 2025 and provided an update on its recent corporate progress. “We are pleased to announce that we have recently achieved our randomization target of 230 patients in the Phase 3 LEVEL study. As we strive to make significant progress executing on our registrational LEVEL program, achievement of this important milestone demonstrates our team’s commitment to rapidly advancing TNX-103,” said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. “The screening period for LEVEL has closed. Patients already screening will have the opportunity to qualify for randomization, which we anticipate finishing this month. We expect to share initial results from LEVEL in the third quarter of 2026.” Mr. Giordano continued, “In parallel, we remain focused on activating clinical sites around the world to advance the global LEVEL-2 study, which we continue to anticipate will complete enrollment by the end of 2027. With a continued focus on execution, we aim to rapidly advance the development of TNX-103, a novel and potential first-in-class therapy for patients with PH-HFpEF who have no approved treatment options for their debilitating disease.” Recent Corporate and Clinical Highlights In November 2025, Tenax hosted a virtual call with key opinion leaders to discuss the treatment landscape for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), as well as its Phase 3 TNX-103 program. In Decembe...

RAP-219’s lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026 RAP- 219 epilepsy portfolio expanded with new program in primary generalized tonic-clonic seizures (PGTCS) on strength of Phase 2a FOS data Phase 2 trial in bipolar mania, development of a long-acting injectable, and other pipeline programs continued to progress Entered into a strategic collaboration and license agreement with Tenacia Biotechnology (Hong Kong) Co., Ltd. to develop and commercialize RAP-219 in Greater China across indications, including focal onset seizures and bipolar mania Ended the year with $490.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today reported financial results for the quarter and full year ended December 31, 2025, and provided a business update. “2025 was a year of strong momentum for Rapport as we advanced our precision neuroscience pipeline and continued building what we believe can become a leading epilepsy portfolio. The compelling Phase 2a results in focal onset seizures strengthened our confidence in the program’s potential best-in-class profile and support our strategy to advance RAP-219 across multiple opportunities within epilepsy,” said Abraham N. Ceesay, chief executive officer of Rapport. “We also continued to advance several other important initiatives, including our Phase 2 bipolar mania trial, development of a long-acting injectable formulation, and additional pipeline candidates - applying our precision medicine...

MIDDLETOWN, R.I., March 10, 2026 (GLOBE NEWSWIRE) -- KVH Industries, Inc., (Nasdaq: KVHI), reported financial results for the quarter and full year ended December 31, 2025 today. The company will hold a conference call to discuss these results at 9:00 a.m. ET today, which can be accessed at investors.kvh.com. Following the call, a replay of the webcast will be available through the company’s website. Fourth Quarter 2025 Highlights Total revenues in the fourth quarter of 2025 increased sequentially from the third quarter of 2025 by $2.1 million, or 7%, to $30.5 million primarily due to an increase in service sales. Total revenues increased by 13% from $26.9 million in the fourth quarter of 2024, primarily due to a $6.0 million increase in service sales, partially offset by a $2.4 million decrease in product sales. Service revenue increased sequentially from the third quarter of 2025 by $2.9 million, or 12%, to $28.3 million in the fourth quarter of 2025. Service revenue increased by $6.0 million, or 27%, in the fourth quarter of 2025 compared to the fourth quarter of 2024. On October 8, 2025, the Company purchased the maritime satellite service business of a satellite services provider operating in the Asia-Pacific region. As a result of the business combination, the Company recognized intangible assets of $3.4 million and goodwill of $0.7 million. Service revenue in the fourth quarter of 2025 included $2.5 million of revenue attributable to the business combination. Net income in the fourth quarter of 2025 was $0.3 million, or $0.02 per share, compared to a net loss of $4.3 million, or $0.22 per share, in the fourth quarter of 2024. Non-GAAP adjusted EBITDA was $3.1 million in the fourth quarter of 2025, compared to $0.5 million in the fourth quarter of 2024. Commenting on the company’s fourth quarter and full year results, Brent C. Bruun, KVH’s Chief Executive Officer, said, “The maritime connectivity market is undergoing a fundamental transformation as LEO satelli...

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectively (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectively Surpassed milestone of more than 10,000 patients treated with CARVYKTI ® CARVYKTI now available across 294 sites worldwide; continued expansion in U.S. community settings Advanced early-stage cell therapy portfolio, including first-patient dosing of in vivo candidates and presentation of first-in-human results for LUCAR-G39D, an allogeneic CAR-T therapy Cash and cash equivalents, and time deposits of $949 million, as of December 31, 2025 SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter and year ended December 31, 2025, and key corporate highlights. “CARVYKTI® continued to build on its leadership in multiple myeloma CAR‑T in 2025, as we reached more than 10,000 patients treated and achieved franchise profitability,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “With expanding capacity and ongoing efforts to broaden adoption, including in the community setting, we are focused on executing against the opportunities ahead while extending our innovation leadership across in vivo and allogeneic programs.” Key Business Developments Achieved CARVYKTI ® franchise profitability for the full year 2025. franchise profitability for the full year 2025. Treated more than 10,000 clinical and commercial patients to date with CARVYKTI ® . . Strengthened manufacturing and supply capabilities, completing the newly expanded portion of the Raritan facility, making it the largest cell therapy manufacturing site in the United States supporting treatment of up to 10,000 patients annually. Expanded gl...

Transition Underway to More Digital, Scalable, Higher Margin Business Fourth quarter Revenue of $77.2 million driven primarily by record Interactive revenue, up 53% year-over-year Fourth quarter Net Operating Income of $11.2 million, Net Loss of $7.2 million and Adjusted Net Loss of $5.1 million Adjusted EBITDA of $32.3 million, up 5% from prior year, generating a record 42% Adjusted EBITDA Margin, driven by all-time-high Interactive Adjusted EBITDA, up 60% year-over-year First quarter 2026 Adjusted EBITDA expected to increase by at least 20% year over year, with full year 2026 Adjusted EBITDA expected to be in the range of $112 million to $118 million1 NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Inspired Entertainment, Inc. (“Inspired” or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. “Our fourth quarter results reflect the strength of our underlying business and the progress we are making in advancing our strategic priorities,” said Brooks Pierce, President and CEO of Inspired. “We delivered record Interactive revenue (+53% YoY) and Adjusted EBITDA (+60% YoY), underscoring the scalability and operating leverage of our digital core growth engine. With digital representing 52% of Adjusted EBITDA2 following the November divestiture of our holiday parks business, we achieved a record Adjusted EBITDA margin for the quarter3. Content continues to be a key differentiator across the portfolio. In Gaming, customers with new terminal deployments in our UK and Greece estates delivered double-digit gross win growth, supporting further share gains. In Virtual Sports, our new Virtual Soccer BetBuilder™ product in Greece is still in its early stages but is already driving increases in total bet volume and gross win, positioning us well for a broader rollout ahead of this summer’s World Cup. We remain focused on investing i...

Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline study completed with top-line results available by year-end 2026 Cash and investments of $439.0 million as of December 31, 2025; runway into 2029 CAMBRIDGE, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2025. “Cullinan Therapeutics is poised to deliver multiple value-driving catalysts across our programs throughout 2026. Strong enrollment momentum for CLN-978 positions us to deliver the first company-sponsored data for a potential best-in-class CD19 T cell engager in autoimmune diseases in the second quarter, followed by important additional data updates throughout the year. CLN-978 is the ideal therapy for immune reset, with the optimal combination of target, CD19, and modality, T cell engager, together with the convenience of subcutaneous administration. This program has the potential to transform the treatment landscape in autoimmune diseases and deliver a compelling commercial opportunity,” said Nadim Ahmed, President and CEO of Cullinan Therapeutics. “We are also pleased to begin the year with strong momentum in our oncology portfolio. With our partner, Taiho, we have completed the second line rolling NDA submission for zipalertinib and have fully enrolled the frontline study, REZILIENT3, both important milestones as zipalertinib moves closer to being available for patients. Finally, after sharing compelling clinical data at ASH 2025 and with U.S. FDA Fast Track Designation, we expect to rapidly advance CLN-0...

Created by Mitch Gould, Founder & CEO of Nutritional Products International, a Proven Model for Building Retail Success in the U.S. Market BOCA RATON, FL / ACCESS Newswire / March 10, 2026 / Mitch Gould, Founder and CEO of Nutritional Products International (NPI), developed the Evolution of Distribution®, a comprehensive market-entry system designed to help international health, wellness, and nutritional brands successfully launch and scale within the U.S. retail marketplace. After decades working with major retailers including Walmart, CVS, Amazon, and GNC, Gould recognized a recurring challenge for global brands: entering the U.S. requires navigating a fragmented network of logistics providers, regulatory consultants, distributors, brokers, marketing agencies, and retail buyers. "The Evolution of Distribution® was created to solve that fragmentation," said Gould. "Instead of brands managing multiple vendors across logistics, compliance, sales, and marketing, we built a unified system that brings every step of U.S. market entry under one coordinated program." Today, the Evolution of Distribution® platform has expanded to provide true end-to-end market entry management, beginning at a brand's international manufacturing facility and extending all the way to U.S. retail shelves and e-commerce platforms. Through enhanced logistics and freight-forwarding capabilities, NPI can now coordinate international transportation from virtually any origin worldwide, moving products via ocean, air, rail, or intermodal freight directly to the Port of Miami and into NPI's U.S. warehouse network. From there, products move through a coordinated system that includes regulatory preparation, distribution, retail introductions, and integrated marketing support. Image Caption: Mitch Gould, founder and CEO of Nutritional Products International (NPI) The Evolution of Distribution® model operates through several core pillars designed to support successful product launches and long-term brand ...

"Accelerating quantum applications for the aerospace industry requires close collaboration between quantum software and high-performance computing," said Christian Weedbrook, Founder and Chief Executive Officer of Xanadu. "Our partnership with AMD brings these capabilities together to address real engineering challenges today. By optimizing how large-scale quantum programs are compiled and simulated, we are helping ensure the aerospace industry is ready to adopt fault-tolerant quantum computing as soon as it becomes available.” “Seeing AMD high-performance compute boost the performance of PennyLane is a clear proof point of how quantum and classical technologies can effectively work together,” said Madhu Rangarajan, Corporate Vice President, Compute and Enterprise AI, AMD. “This work further underscores the importance of seamless integration between classical and quantum computing. The work between AMD and Xanadu expands the boundaries of what is possible for users investigating hybrid quantum/classical computing using AMD compute today.” Aerospace engineers rely on computational fluid dynamics (CFD) simulations to optimize design and enhance aircraft efficiency. Xanadu, powered by the AMD DevCloud, has successfully demonstrated CFD simulations within a hybrid quantum-classical program, showcasing the significant potential of quantum computing for the industry. The work centered on the compilation and execution of a CFD model with 256x256 matrix elements. This hybrid program utilized 20 qubits and approximately 35 million quantum gates, pushing the boundaries of current CFD quantum simulations. As the industry advances toward fault-tolerant quantum computing, the ability to compile and optimize programs of this scale will become a critical competitive advantage. This milestone demonstrates that Xanadu and AMD can support next-generation quantum-classical applications by combining their respective technologies and expertise, helping transition quantum computing from ...

2026-03-10 | ORCL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Oracle Corporation Investors with Losses Have Opportunity to Lead Class Action Lawsuit! | NYSE:ORCL | Press Release Stockhouse

Good morning . Donald Trump is weighing options to ease pain at the pump for motorists. Hedge funds are also feeling the sting, after suffering huge losses in last week’s market mayhem. And Australia grants humanitarian visas to Iranian soccer players who refused to sing their national anthem. Listen to the day’s top stories . S&P 500 Futures 6,808 +0.10% Nasdaq 100 Futures 25,044.25 +0.21% Bloomberg Dollar Spot Index 1,199.07 -0.20% Donald Trump is considering a menu of possible options to combat surging gasoline prices . One idea under consideration is tapping into emergency stockpiles. Here’s our explainer on how that might help. The rising costs facing motorists has given Democrats another economic pain point to emphasize heading into midterm elections. Several Senate Democrats are threatening to force numerous war powers votes and otherwise disrupt the chamber unless Republicans agree to hold public hearings on the reasons behind the attacks on Iran. Some relief as oil prices tumbled after Trump indicated yesterday the war may end soon . But those moves were modest compared with Monday’s wild gyrations , which left veteran oil traders frazzled. Some of the world’s biggest hedge funds suffered hundreds of millions of dollars in losses last week riding the rollercoaster. A Pentagon official said there’s little chance of restarting talks with Anthropic over military use of its AI tools after the company sued to challenge a government decision labelling it a supply-chain risk. Elsewhere, Apple’s efforts to pivot away from China are bearing fruit—the company now makes a quarter of its iPhones in India. Iran War Has Airlines Reviewing Growth Plans as Fuel Surges Until last month, airlines couldn’t get new aircraft fast enough, with both Airbus SE and Boeing Co. struggling to keep up with surging demand. Read the Story Trump’s efforts to force Republicans to pass a partisan overhaul of voting laws risks bringing congressional business to a halt with no clear path to s...

Pinkerton Wealth LLC reduced its holdings in Palantir Technologies Inc. (NASDAQ:PLTR - Free Report) by 15.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,938 shares of the company's stock after selling 3,956 shares during the period. Pinkerton Wealth LLC's holdings in Palantir Technologies were worth $3,820,000 at the end of the most recent reporting period. Other institutional investors have also recently bought and sold shares of the company. Occidental Asset Management LLC increased its holdings in shares of Palantir Technologies by 2.8% in the 3rd quarter. Occidental Asset Management LLC now owns 1,964 shares of the company's stock valued at $358,000 after purchasing an additional 53 shares during the period. Gallacher Capital Management LLC lifted its position in shares of Palantir Technologies by 2.2% in the third quarter. Gallacher Capital Management LLC now owns 2,452 shares of the company's stock worth $447,000 after purchasing an additional 53 shares in the last quarter. Bare Financial Services Inc boosted its holdings in shares of Palantir Technologies by 54.5% during the third quarter. Bare Financial Services Inc now owns 156 shares of the company's stock worth $28,000 after purchasing an additional 55 shares during the period. Lionshead Wealth Management LLC boosted its holdings in shares of Palantir Technologies by 0.4% during the third quarter. Lionshead Wealth Management LLC now owns 13,130 shares of the company's stock worth $2,395,000 after purchasing an additional 56 shares during the period. Finally, Ellenbecker Investment Group grew its position in Palantir Technologies by 3.6% during the third quarter. Ellenbecker Investment Group now owns 1,619 shares of the company's stock valued at $295,000 after purchasing an additional 57 shares in the last quarter. 45.65% of the stock is currently owned by institutional investors and hedge funds....

Pinkerton Wealth LLC acquired a new position in shares of Advanced Micro Devices, Inc. (NASDAQ:AMD - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 19,891 shares of the semiconductor manufacturer's stock, valued at approximately $3,218,000. Other hedge funds have also recently added to or reduced their stakes in the company. Impax Asset Management Group plc boosted its holdings in shares of Advanced Micro Devices by 326.5% during the third quarter. Impax Asset Management Group plc now owns 52,068 shares of the semiconductor manufacturer's stock valued at $8,424,000 after acquiring an additional 39,861 shares during the period. Global Retirement Partners LLC acquired a new stake in shares of Advanced Micro Devices in the 2nd quarter worth about $4,519,000. Swiss National Bank increased its holdings in shares of Advanced Micro Devices by 7.5% in the 2nd quarter. Swiss National Bank now owns 4,917,975 shares of the semiconductor manufacturer's stock worth $697,861,000 after acquiring an additional 341,000 shares during the period. New York State Common Retirement Fund lifted its position in Advanced Micro Devices by 8.4% in the 2nd quarter. New York State Common Retirement Fund now owns 2,239,239 shares of the semiconductor manufacturer's stock valued at $317,748,000 after purchasing an additional 172,745 shares during the last quarter. Finally, Zweig DiMenna Associates LLC lifted its position in Advanced Micro Devices by 127.6% in the 3rd quarter. Zweig DiMenna Associates LLC now owns 72,602 shares of the semiconductor manufacturer's stock valued at $11,746,000 after purchasing an additional 40,708 shares during the last quarter. Institutional investors and hedge funds own 71.34% of the company's stock. Get Advanced Micro Devices alerts: Sign Up Insider Activity In other news, SVP Ava Hahn sold 2,442 shares of the company's stock in a transaction on Friday, January 16th. The sto...

Pinkerton Wealth LLC increased its stake in Qualcomm Incorporated (NASDAQ:QCOM - Free Report) by 17.4% during the third quarter, according to its most recent filing with the SEC. The fund owned 50,195 shares of the wireless technology company's stock after buying an additional 7,446 shares during the quarter. Qualcomm accounts for approximately 0.9% of Pinkerton Wealth LLC's portfolio, making the stock its 20th largest holding. Pinkerton Wealth LLC's holdings in Qualcomm were worth $8,350,000 as of its most recent SEC filing. A number of other large investors have also added to or reduced their stakes in QCOM. Harbor Capital Advisors Inc. raised its position in Qualcomm by 72.2% in the third quarter. Harbor Capital Advisors Inc. now owns 155 shares of the wireless technology company's stock worth $26,000 after acquiring an additional 65 shares during the period. Cloud Capital Management LLC bought a new position in shares of Qualcomm during the 3rd quarter valued at approximately $27,000. Winnow Wealth LLC bought a new position in shares of Qualcomm during the 2nd quarter valued at approximately $32,000. Lavaca Capital LLC purchased a new stake in shares of Qualcomm during the 2nd quarter worth approximately $32,000. Finally, Guerra Advisors Inc bought a new stake in shares of Qualcomm in the 3rd quarter worth approximately $39,000. Hedge funds and other institutional investors own 74.35% of the company's stock. Get Qualcomm alerts: Sign Up Wall Street Analyst Weigh In QCOM has been the topic of several research analyst reports. Susquehanna downgraded Qualcomm from a "positive" rating to a "neutral" rating and set a $140.00 price objective on the stock. in a research note on Thursday, February 5th. Sanford C. Bernstein reissued an "outperform" rating and issued a $200.00 target price on shares of Qualcomm in a research report on Monday, February 2nd. Rosenblatt Securities lowered their target price on Qualcomm from $225.00 to $190.00 and set a "buy" rating on the st...

Martin Johnson, England’s World-Cup winning skipper, believes there is no huge mystery to being a great captain. “If you haven’t got a good team it doesn’t matter how good a captain you are,” he said on the Rugby Legends podcast before the start of this year’s Six Nations. And if anyone is qualified to provide such a definitive judgment it is unquestionably him. To suggest that calm, sure-footed leadership is irrelevant in top-level sport, however, is another matter. Even the greatest sides need decisive, intelligent direction, regardless of who supplies it. The other imperative is to have everyone pulling in the same direction. Shared responsibility and collective ownership are everything, particularly in rugby where the all-for-one, one-for-all ethos is fundamental. Hence why the public on-field spat between Maro Itoje and his fly-half Fin Smith early in the second half of England’s 23-18 defeat in Rome has raised eyebrows. England were ahead 12-10 and had just won a scrum penalty near the Italian line. Immediately it felt like a revealing moment: would they kick for the posts or, in search of potentially greater reward, double down on their momentum, go to the corner and set up a close-range lineout drive? Jamie George, England’s former captain, held up three fingers to Itoje to indicate his preference. Ellis Genge, however, feigned to take a quick tap before appearing to suggest, with a smile, that they should kick to the corner. When Smith also double-checked the call, Itoje’s patience snapped. “Don’t argue with me, take the three!” he screamed at his young fly-half. If ever there was a snapshot of the heightened pressure of Test rugby this was surely it. Itoje is not a habitual screamer; indeed, Steve Borthwick specifically cited his measured demeanour when he promoted the lock to the captaincy. “It struck me that Maro thinks really well under pressure,” stressed the head coach. “He stays calm under pressure.” Less so at the weekend. Happily for all involved, ...

在“双碳”目标引领与高水平对外开放格局下，绿色金融已成为连接国内国际、赋能低碳发展的核心纽带。工商银行上海市分行坚守服务实体经济与绿色发展使命，以全球化视野、专业化服务、高效化方案，为境内外绿色能源项目注入金融活水，助力企业低碳转型与海外高质量发展，书写金融支持“一带一路”绿色合作的生动实践。 寰泰集团是国内专注于风电、光伏等清洁能源投资、建设与运营的优质民营企业，积极布局海外清洁能源市场。在风能资源优越的哈萨克斯坦，企业规划建设一座总投资达4.23亿元的风电场，却在关键的项目融资环节面临挑战。作为该项目融资牵头行，工行上海市分行闻令而动、快速响应，第一时间组建跨层级、跨部门的专项服务团队，以“精锐作战”模式全力攻坚项目融资。 工行服务团队以畅通跨境融资动脉为目标，昼夜奋战、精准施策，反复打磨优化融资方案，严密把控项目各环节风险，高效推进审批、授信、银团组建等全流程工作，跨越中哈两国时空与业务壁垒，打通跨境绿色金融服务通道。在工行上海市分行的全力保障下，项目顺利完成所有提款条件并成功实现银团提款，为风电场建设提供了及时、足额的关键资金支持，保障项目全速落地推进。 该风电项目建成后，年发电量可达3.3亿千瓦时，不仅将有效优化哈萨克斯坦能源供给结构，推动当地清洁能源替代与低碳减排，更以金融力量赋能“中国制造”风电技术出海，打造出中国绿色金融服务海外项目的标杆名片，成为中哈能源合作与绿色发展的典范。 “十四五”以来，工行上海市分行坚决贯彻落实国家绿色发展战略，深度对接上海高水平对外开放要求，严格落实工总行绿色金融顶层布局，持续健全绿色金融体制机制，制定绿色金融高质量发展行动方案，推出四大领域二十条具体举措，依托绿色金融委员会统筹引领作用，全方位、多层次推进绿色金融业务提质增效。截至目前，该行绿色贷款总量已突破2500亿元，规模持续稳居同业首位，以硬核实力为经济社会全面绿色低碳转型提供强劲金融支撑。 从跨境清洁能源项目到本土绿色产业发展，从机制创新到规模领跑，工商银行上海市分行以绿色金融为笔，以金融活水为墨，持续助力企业低碳转型、服务国家“双碳”目标、深化国际绿色合作，未来还将继续深耕绿色金融主赛道，不断创新产品服务、拓展合作边界，为实现碳达峰碳中和目标、推动绿色高质量发展贡献金融力量。

MattGush/iStock Editorial via Getty Images PG&E ( PCG ) is a major utility company focused primarily on California that has been called out for high electric rates and ineffective wildfire management. The company is one we last discussed in December , and since then it has outperformed the S&P 500 by 17%. Despite that, as we'll see in this article, the company's recent earnings and the focus they show on the company's long-term potential make it a valuable investment. PG&E 2025 Overview PG&E had a strong 2025 and expects to continue that strength into 2026. PG&E Investor Presentation PG&E 2025 Results Investor Presentation The company had $1.5/share in 2025 full-year EPS, putting it at a low double-digit P/E and representing 10% growth over 2024. Going into 2026, the company expects another 10% growth to $1.65/share in EPS. Through the end of the decade, PG&E expects almost double-digit EPS growth with no fresh equity to be released. PG&E Investor Presentation PG&E has done this with electric rates 11% lower than 2024. With the growth of large load projects (data centers), the company sees 3.6 GW of potential additional demand. The company is moving towards a 20% by 2028 dividend payout, which is fairly minor, but as the company improves its balance sheet, growth will be able to accelerate. PG&E Wildfires Among PG&E’s largest risks are major wildfires, which can devastate cities and cost tens of billions. PG&E Investor Presentation The state of California has worked with the major utilities to help insure wildfire risk in exchange for major asset upgrades. For 2023, 2024, and 2025, PG&E has had no structures destroyed in PG&E-attributable wildfires. The company has to help contribute as a stakeholder to the California wildfire fund, but predictable expenses are much better than uncapped liability. PG&E Investment Model PG&E now needs to figure out how to handle decades of underinvestment without drastically increasing rates. PG&E Investor Presentation The company se...

Sterling ticks higher as lower oil prices temper inflation concerns Reuters

JHVEPhoto/iStock Editorial via Getty Images How I Can Still Be Bullish Even After The Stock Falling PayPal ( PYPL ) can be a very polarizing stock to talk about. On one hand you have people who've been invested for years and rode the stock price up to the record levels of $300 per share and haven’t sold since. Then on the other hand you have those who see it as a failing business that won’t stand the test of time. Even though it generated over $33 billion in revenues and $6.4 billion in operating cash flows. I’ve written a total of two times before about this company. It isn’t easy to say that I haven’t done that well with my ratings and recommendations though. The first article came out on September 26 and was in fact my third on the site. Since then the stock has fallen by 30.53% at the time of writing this. Previous Coverage (Seeking Alpha / Author) The second time I wrote about it was on December 19th and since then the stock has fallen by 21.84%. Much of the losses have happened in just this year as shares are down nearly 20%, most of that happening after the last earnings report when it missed on the top line and normalized EPS, but beat on GAAP EPS instead. I hope that most people who follow me realize that my ratings aren’t for the short-term. I don’t rate a company a strong buy and then turn around and downgrade it to a buy or even sell just because of a small hiccup or change of market sentiment. I look at my investments that I have exposure to (which PYPL falls within) as long-term and multi-year holdings. I’m sticking with a Strong Buy rating because much of the qualities I’ve echoed before I still think are true. PYPL is a massive cash flow generating machine that is actively using this to reward shareholders. Just because the market hasn’t caught up to this yet doesn't make it a bad investment. With the share price falling but PYPL’s financial numbers still looking strong they’ll continue to get a good “bang for their buck” with buybacks. But there are...

Revenue was $2.2 billion, an increase of 6.1% over the prior year, including organic growth of 5.5% Net income totaled $38.8 million, or $0.64 per diluted share, as compared to $43.6 million or $0.69 in the prior year Adjusted net income was $50.4 million, or $0.83 per diluted share, versus $55.3 million, or $0.87, in the prior year Adjusted EBITDA was $117.8 million, versus $120.6 million last year Operating cash flow was $62.0 million and free cash flow totaled $48.9 million, both up significantly over the prior year The Company repurchased $91.1 million of common stock during the quarter at an average price of $44.13 per share NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- ABM (NYSE: ABM), a leading provider of facility, engineering and infrastructure solutions, today announced financial results for its fiscal first quarter ended January 31, 2026. “ABM is off to a solid start to fiscal 2026, delivering strong organic revenue growth of 5.5% and meaningful improvement in operating cash flow and free cash flow,” said Scott Salmirs, President and Chief Executive Officer. “Growth was broad-based across our portfolio, reflecting healthy demand in our end markets and our team’s continued success in expanding client relationships. This performance reinforces our confidence in the strength and resiliency of our business.” Mr. Salmirs continued, “From a margin perspective, results were below our expectations, driven primarily by Technical Solutions, which as we’ve noted in the past, is inherently project-driven and can vary quarter to quarter. This period was impacted by project timing, including temporary weather-related delays, as well as service mix, resulting in approximately $0.05 of EPS pressure relative to our internal plan. Business & Industry and Manufacturing & Distribution, however, performed in line with our expectations reflecting the impact of the new and amended contracts we discussed on our third quarter call, and Education delivered another quarter of strong...